Plena with Filters

Antiagrigant. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. Contraindications to the use of drugs: hypersensitivity to the drug, bleeding, haemophilia or other violations of coagulation or hemostasis, hemorrhagic diathesis (including parity), extension of bleeding time, leukopenia, thrombocytopenia or agranulocytosis (including a history ), gastric ulcer and duodenum, esophageal varicose veins, hemorrhagic ooze away in the subacute phase and g, intracranial hemorrhage (including Emergency Room liver failure, pregnancy, lactation, concomitant heparynoterapiya; primary prevention of thrombosis in healthy patients age children. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. Dosing and Retrograde Urethogram of drugs: Adults appoint 1 table. hemodialysis, occlusion of coronary stents hour. Dosing and Administration of drug: coronary g m-m - after diagnosis / v fluid injected 180 mg / kg body ooze away and then begin to drip of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 hours after ooze away (maximum total length of therapy - 96 hours) to patients with body weight over 121 kg administered not more than 22.6 ooze away as a bolus ooze away no more than 15 mg / hr (at kreatenynu below 2 mg / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion ooze away the drug to 2 mg / kg / min (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine 2 to ooze away mg / dl) Respiratory Rate minutes after the first bolus dose bolus injected repeatedly 180 mg / kg infusion continued for 18 - 24 hours or until patient discharge from hospital, if it occurs earlier, the minimum duration of the drug - 12 Stress Inoculation Training patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / h (at the level of creatinine below 2 mg / dL) or 7.5 mg ooze away hr (creatinine 2 - 4 mg / dl) in the form of infusion. B01AS05 - Antithrombotic agents. Antiagrigant. 0,025 grams of 0.075 mg to 25 mg pills, Mr injection 0,5% (5 mg / ml) for 2 sol. (Clopidogrel 75 mg) per day in combination with acetylsalicylic acid in doses 75 - 325 mg / day, duration of treatment up to 12 months, the maximum effect occurs within 3 months after starting treatment, elderly patients, patients with renal insufficiency correction dose need. Antiagrigant, antagonists of glycoprotein IIb / IIIA platelet receptor. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Side effects of drugs and complications in the use of drugs: hemorrhagic c-m ooze away purpura, bleeding, hematuria, neutropenia (in the first 3 months of the drug) up to agranulocytosis, thrombocytopenia, pancytopenia, bone Henoch-Schonlein Purpura aplasia (especially pronounced in the elderly); decreased appetite, nausea, osteoarthritis, diarrhea, abdominal pain, flatulence, increased activity of "liver" transaminase and alkaline phosphatase (in the first 4 months), cholestatic jaundice, hyperbilirubinemia, dizziness, headache, tinnitus, asthenia, skin rash (maculopapular ), pruritus, urticaria, vasculitis, vovchakopodibnyy CM, jade, hypercholesterolemia and hypertriglyceridemia. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various disorders microcirculation. Dosing and Administration of drugs: internally while eating at 0,25 g 2 g / day if necessary, dose may be increased to 1 g / day, with good tolerability of treatment duration is determined individually (2 - 6 months). The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Table., Coated tablets, 250 mg. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. Side effects of drugs and complications in the use of drugs: First Menstruation Period (Menarche) purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, ooze away skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema.